JP5072604B2 - １−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩 - Google Patents

１−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩 Download PDF

Info

Publication number
JP5072604B2
JP5072604B2 JP2007554541A JP2007554541A JP5072604B2 JP 5072604 B2 JP5072604 B2 JP 5072604B2 JP 2007554541 A JP2007554541 A JP 2007554541A JP 2007554541 A JP2007554541 A JP 2007554541A JP 5072604 B2 JP5072604 B2 JP 5072604B2
Authority
JP
Japan
Prior art keywords
chlorophenyl
propoxy
propyl
pharmaceutical composition
piperidine monohydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007554541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530050A (ja
JP2008530050A5 (enExample
Inventor
エメ． ラガ，マヌエル
サラレス，ホアン
ゲレーロ，マルタ
グリエッタ，アントニオ
アラン，ジャン−ミシェル
シュワルツ，ジャン−シャルル
スタルク，ホルガー
シュナック，バルター
リグノー，グザビエ
ルコント，ジャンヌ−マリー
ロビン ガネリン，シャロン
Original Assignee
ビオプロジェ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34938687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5072604(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビオプロジェ filed Critical ビオプロジェ
Publication of JP2008530050A publication Critical patent/JP2008530050A/ja
Publication of JP2008530050A5 publication Critical patent/JP2008530050A5/ja
Application granted granted Critical
Publication of JP5072604B2 publication Critical patent/JP5072604B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
JP2007554541A 2005-02-10 2006-02-06 １−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩 Expired - Lifetime JP5072604B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100942.1 2005-02-10
EP05100942A EP1690858B1 (en) 2005-02-10 2005-02-10 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PCT/EP2006/050703 WO2006084833A1 (en) 2005-02-10 2006-02-06 Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine

Publications (3)

Publication Number Publication Date
JP2008530050A JP2008530050A (ja) 2008-08-07
JP2008530050A5 JP2008530050A5 (enExample) 2009-04-02
JP5072604B2 true JP5072604B2 (ja) 2012-11-14

Family

ID=34938687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007554541A Expired - Lifetime JP5072604B2 (ja) 2005-02-10 2006-02-06 １−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩

Country Status (22)

Country Link
US (2) US8207197B2 (enExample)
EP (2) EP1690858B1 (enExample)
JP (1) JP5072604B2 (enExample)
KR (1) KR101344271B1 (enExample)
CN (1) CN101155793B (enExample)
AR (1) AR054734A1 (enExample)
AT (2) ATE391716T1 (enExample)
CA (1) CA2597016C (enExample)
CY (1) CY1108428T1 (enExample)
DE (2) DE602005005941D1 (enExample)
DK (1) DK1846384T3 (enExample)
ES (1) ES2309948T3 (enExample)
HR (1) HRP20080446T3 (enExample)
ME (1) ME01103B (enExample)
MX (1) MX2007009574A (enExample)
PL (1) PL1846384T3 (enExample)
PT (1) PT1846384E (enExample)
RS (1) RS50624B (enExample)
SI (1) SI1846384T1 (enExample)
TW (1) TWI393711B (enExample)
UY (1) UY29369A1 (enExample)
WO (1) WO2006084833A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
AU2010214101A1 (en) 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
KR20120035183A (ko) 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
JP2013504580A (ja) 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
WO2014199935A1 (ja) * 2013-06-10 2014-12-18 株式会社エム・エス・エス 小胞体ストレスシグナルを抑制することによる，薬剤の副作用としての体重増加や肥満を防止するために用いられる肥満防止剤
CN103435575A (zh) * 2013-08-06 2013-12-11 中国人民解放军军事医学科学院毒物药物研究所 1-（ 3-（ 3-（ 4-氯苯基）丙氧基）丙基）哌啶盐酸盐的制备方法
CN104447620B (zh) * 2014-11-28 2016-05-04 瑞阳制药有限公司 1-[3-[3-(4-氯苯基)丙氧基]丙基]-哌啶盐酸盐的制备方法
EP3239138A1 (en) 2016-04-25 2017-11-01 Sandoz Ag Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
IT201900013941A1 (it) 2019-08-05 2021-02-05 Procos Spa PROCESSO PER LA SINTESI DI PITOLISANT HCl
CN110804026B (zh) * 2019-11-18 2022-04-01 苏州永健生物医药有限公司 1- (3- (3-（4-氯苯基）丙氧基)丙基)哌啶盐酸盐的合成方法
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US11623920B2 (en) 2021-06-07 2023-04-11 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
US20250059145A1 (en) * 2021-12-29 2025-02-20 Biophore India Pharmaceuticals Pvt. Ltd. Solid forms of 1-{3-[3-(4-chlorophenyl) propoxy] propyl} piperidine hydrochloride and process for the preparation thereof
US20250281475A1 (en) * 2022-05-04 2025-09-11 Msn Laboratories Private Limited, R & D Center A pharmaceutical composition of pitolisant hydrochloride and their process for the preparation
WO2024084379A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD)
EP4374854A1 (en) * 2022-11-28 2024-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical mixture comprising amorphous pitolisant
JP2026511788A (ja) 2023-03-31 2026-04-14 ビオプロジェ・ファルマ ピトリサント塩酸塩の多形形態
EP4681704A1 (en) 2024-07-18 2026-01-21 BIOPROJET Pharma New formulations of pitolisant
CN122374013A (zh) 2023-10-16 2026-07-10 生物计划制药公司 替洛利生的新制剂和使用方法
EP4732903A1 (en) 2024-10-28 2026-04-29 BIOPROJET Pharma Co-crystals of pitolisant hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications

Also Published As

Publication number Publication date
EP1690858A1 (en) 2006-08-16
TWI393711B (zh) 2013-04-21
CY1108428T1 (el) 2014-04-09
CA2597016A1 (en) 2006-08-17
CN101155793A (zh) 2008-04-02
US8354430B2 (en) 2013-01-15
PL1846384T3 (pl) 2009-01-30
RS50624B (sr) 2010-06-30
JP2008530050A (ja) 2008-08-07
HRP20080446T3 (en) 2008-10-31
UY29369A1 (es) 2006-05-31
SI1846384T1 (sl) 2008-12-31
ES2309948T3 (es) 2008-12-16
DK1846384T3 (da) 2008-11-17
KR20070101381A (ko) 2007-10-16
WO2006084833A1 (en) 2006-08-17
MX2007009574A (es) 2007-09-25
AR054734A1 (es) 2007-07-11
TW200639157A (en) 2006-11-16
US8207197B2 (en) 2012-06-26
CA2597016C (en) 2013-01-15
EP1846384A1 (en) 2007-10-24
PT1846384E (pt) 2008-10-21
DE602006001938D1 (de) 2008-09-04
EP1690858B1 (en) 2008-04-09
ME01103B (me) 2013-03-20
US20120289546A1 (en) 2012-11-15
ATE402154T1 (de) 2008-08-15
US20080221162A1 (en) 2008-09-11
ATE391716T1 (de) 2008-04-15
CN101155793B (zh) 2015-05-20
EP1846384B1 (en) 2008-07-23
KR101344271B1 (ko) 2013-12-26
DE602005005941D1 (de) 2008-05-21

Similar Documents

Publication Publication Date Title
JP2008530050A (ja) １−［３−［３−（４−クロロフェニル）プロポキシ］プロピル］−ピペリジン一塩酸塩
JP2026053405A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
JP6933964B2 (ja) ヘテロアリール化合物およびそれらの使用方法
KR20030015390A (ko) 지질 풍부 플라크 퇴축제
WO1999020620A1 (en) Isoquinoline derivative and drug
KR20120136422A (ko) 치환된 모르폴린 및 티오모르폴린 유도체
WO2010126002A1 (ja) ヘテロ環スルホンアミド化合物を含有する医薬
WO2001097810A2 (en) Use of therapeutic benzamide derivatives
AU2022229695A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
EA029313B1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
JPH037257A (ja) ピリジン誘導体及びそれを有効成分とする向精神剤
EP0929550A1 (fr) DERIVES DE $i(N)-(BENZOTHIAZOL-2-YL)PIPERIDINE-1-ETHANAMINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JPH05331129A (ja) カフェー酸誘導体及びそれを含む医薬組成物
JPH04312585A (ja) ピロリジン誘導体
JP2006528963A (ja) オピオイド受容体リガンドとしてのジアリールメチリデンピペリジン誘導体、その製造およびその使用
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
HK40091505A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
JP2002255808A (ja) リピド・リッチ・プラーク退縮剤
RU2339627C2 (ru) Новые арилпиперазиниловые соединения
JP2007500740A (ja) ジアリールメチリデンピペリジン誘導体、その製造およびその使用
JPH03220184A (ja) シクロペンタノン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120814

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120821

R150 Certificate of patent or registration of utility model

Ref document number: 5072604

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150831

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term